hydroxyflutamide has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, C; Han, R; Li, Y; Messing, E; Niu, Y; Shang, Z; Shyr, CR; Tian, J; Yeh, S; Zhang, M | 1 |
| Bao, BY; Cai, Y; Chang, C; Hsu, CL; Huang, J; Lee, YF; Li, G; Liu, S | 1 |
2 other study(ies) available for hydroxyflutamide and Disease Exacerbation
| Article | Year |
|---|---|
Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cell Line, Tumor; Cell Movement; Cell Survival; Curcumin; Disease Progression; Drug Synergism; Female; Flutamide; Gene Expression; Humans; Integrin alpha5beta1; Interleukin-6; Macrophages; Mice; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Fluorescent Antibody Technique; Flutamide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; NF-kappa B; Nitrobenzenes; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Transfection; Tumor Cells, Cultured; Up-Regulation | 2008 |